The HemOnc Pulse

Dr. Usmani Highlights Myeloma Presentations from SOHO 2024

On this episode of "The HemOnc Pulse," Saad Usmani, MD, of the Memorial Sloan Kettering Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss notable presentations on multiple myeloma from the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.

Covering MDS Updates at SOHO 2024 With Dr. Venugopal

On this episode of "The HemOnc Pulse," Chadi Nabhan, MD, MBA, FACP, is joined by Sangeetha Venugopal, MD, of the Sylvester Comprehensive Cancer Center at the University of Miami, to highlight data on myelodysplastic syndromes (MDS) presented at the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.

AML News From SOHO 2024 With Dr. Daver

On this episode of "The HemOnc Pulse," Naval Daver, MD, of the MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss news on acute myeloid leukemia coming out of the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.

Dr. Shadman Shares SOHO 2024 Data On CLL

On this episode of "The HemOnc Pulse," Mazyar Shadman, MD, MPH, of the Fred Hutchinson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to highlight some of the notable presentations on chronic lymphocytic leukemia coming out of the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.

Dr. Bose on MPN Highlights From SOHO 2024

On this episode of "The HemOnc Pulse," Prithviraj Bose, MD, of the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss some of the important data on myeloproliferative neoplasms that were presented at the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.

Part Two: The Question of MRD in CLL Therapy

In part two of this episode, Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center; Meghan Thompson, MD, of Memorial Sloan Kettering Cancer Center; and Alan Skarbnik, MD, of Novant Health, continue to explore the role of measurable residual disease (MRD) in the treatment of patients with chronic lymphocytic leukemia (CLL).
“The HemOnc Pulse” was live for in Chicago, Illinois, on May 3-4 and featured host Chadi Nabhan, MD, MBA, FACP, moderating panels of academic and clinical experts who delved into unanswered questions in various hematologic malignancies. 

Dr. Osman on Identifying and Treating High-Risk MDS

On “The HemOnc Pulse,” Chadi Nabhan, MD, MBA, FACP, met with Afaf Osman, MD, an Assistant Professor at the University of Utah Huntsman Cancer Center, to discuss how high-risk myelodysplastic syndromes (MDS) are distinct from lower-risk classifications and how to approach treatment.

Dr. Rami Komrokji on Trends in Real-World MDS Care

On “The HemOnc Pulse,” Chadi Nabhan, MD, MBA, FACP, spoke with Rami Komrokji, MD, Vice Chair of the Malignant Hematology Department at Moffitt Cancer Center in Tampa, Florida, about the state of myelodysplastic syndromes (MDS) care. Moffitt Cancer Center is home to a large MDS database, with clinical information on nearly 6,000 patients, a trove of real-world MDS data.

Part One: The Question of MRD in CLL Therapy

Part one of this episode explores questions in measurable residual disease (MRD) and chronic lymphocytic leukemia (CLL) with Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center; Meghan Thompson, MD, of Memorial Sloan Kettering Cancer Center; and Alan Skarbnik, MD, of Novant Health.
“The HemOnc Pulse” was live for in Chicago, Illinois, on May 3-4 and featured host Chadi Nabhan, MD, MBA, FACP, moderating panels of academic and clinical experts who delved into unanswered questions in various hematologic malignancies. 

‘The HemOnc Pulse’ Live: Unanswered Questions in T-Cell Lymphoma

At the “HemOnc Pulse” Live meeting in Chicago, an expert panel explores unanswered questions in T-cell lymphoma management. The panelists were Mehdi Hamadani, MD, a Professor of Internal Medicine at the Medical College of Wisconsin, Andrew Evens, DO, MBA, MSc, Deputy Director for Clinical Services at Rutgers Cancer Center, and Barbara Pro, MD, a Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons.